Superluminal Medicines secured up to $1.3 billion in a collaboration deal with Eli Lilly to develop small-molecule therapies targeting undisclosed G protein-coupled receptors (GPCRs) implicated in cardiometabolic diseases and obesity. The agreement grants Lilly exclusive rights for development and commercialization post clinical candidate nomination. This major investment reflects confidence in Superluminal’s machine learning-powered GPCR drug discovery platform and Lilly’s commitment to diversifying its obesity treatment pipeline.